Respiratory therapy

Verona Pharma Announces August 2020 Virtual Investor Conference Participation

Monday, August 3, 2020 - 7:00am

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.

Key Points: 
  • Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.
  • If successfully developed and approved, Verona Pharmas product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound.
  • Ensifentrine also has potential applications in cystic fibrosis, asthma and other respiratory diseases.
  • For more information, please visit www.veronapharma.com .

Philips responds to Congressional report

Friday, July 31, 2020 - 2:15pm

Philips is supporting healthcare providers in the U.S. and globally to combat the COVID-19 pandemic, said Frans van Houten, CEO of Royal Philips.

Key Points: 
  • Philips is supporting healthcare providers in the U.S. and globally to combat the COVID-19 pandemic, said Frans van Houten, CEO of Royal Philips.
  • We do not recognize the conclusions in the subcommittees report, and we believe that not all the information that we provided has been reflected in the report.
  • I would like to make clear that at no occasion, Philips has raised prices to benefit from the crisis situation.
  • Philips is producing and delivering this ventilator to HHS in line with the agreed delivery schedule.

DGAP-News: Corona-related precautious free capacities reserved as a precaution in the second quarter of 2020 led to a decline in sales and earnings in the Group - a reliable forecast for the 2020 financial year is not yet possible

Friday, July 31, 2020 - 11:02am

From mid-March to mid-June MEDICLIN's acute clinics had cancelled all deferrable operations and increased ventilator capacity by 40 %.

Key Points: 
  • From mid-March to mid-June MEDICLIN's acute clinics had cancelled all deferrable operations and increased ventilator capacity by 40 %.
  • is reported for the 1st half of 2020 (1st half of 2020: EUR 6.1 mill.).
  • Sales in the post-acute segment amounted to EUR 187.9 mill., a decline of EUR 19.4 mill.
  • The development of occupancy rates at the end of the second quarter 2020 show that business in the post-acute clinics is picking up again.

McGill University, Montreal General Hospital Foundation and HeroX Crowdsource to Develop Affordable Ventilator and Save Lives

Tuesday, July 28, 2020 - 3:32pm

This is phase two of the Code Life Ventilator Challenge , which invited thousands of innovators to design an affordable ventilator.

Key Points: 
  • This is phase two of the Code Life Ventilator Challenge , which invited thousands of innovators to design an affordable ventilator.
  • "COVID-19 has shown us the importance of mobilizing solvers from around the world," said Christian Cotichini, CEO, HeroX.
  • The Candidate team then will make their pitch to the Finalists of the Code Life Ventilator Challenge .
  • HeroX offers a turnkey, easy-to-use platform that supports anyone, anywhere, to solve everyday business and world challenges using the power of the crowd.

Sema4 Increases Capacity to Process up to 15,000 COVID-19 Viral Tests a Day While Continuing to Deliver a 24-48 Hour Turnaround Time

Tuesday, July 28, 2020 - 1:00pm

Sema4 can also support higher education institutions seeking to reopen their campuses and protect the health of students, faculty, and staff.

Key Points: 
  • Sema4 can also support higher education institutions seeking to reopen their campuses and protect the health of students, faculty, and staff.
  • In addition to being able to process up to 15,000 COVID-19 viral tests per day in its Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited laboratory, Sema4 can also process 5,000 antibody tests per day.
  • For viral tests, Sema4 accepts nasopharyngeal swabs and oropharyngeal swabs, which are collected by a healthcare provider or at an authorized collection site.
  • The COVID-19 viral tests used by Sema4 are manufactured by PerkinElmer, and the antibody tests are run on the Abbott Alinity system.

Global Allergic Asthma Therapeutics Market to Surpass US$ 8,209.0 Million by End of 2027, Says Coherent Market Insights

Monday, July 27, 2020 - 2:50pm

According to Coherent Market Insights, the global allergic asthma therapeutics market is estimated to be valued at US$ 6,704.8 million in 2020 and is expected to rise at a CAGR of 2.93% during the forecast period (2020-2027).

Key Points: 
  • According to Coherent Market Insights, the global allergic asthma therapeutics market is estimated to be valued at US$ 6,704.8 million in 2020 and is expected to rise at a CAGR of 2.93% during the forecast period (2020-2027).
  • The global allergic asthma therapeutics market is expected to witness significant growth owing to drug approvals and strategic collaborations among market players.
  • Such factors are expected to support the growth of allergic asthma therapeutics market size.
  • The global allergic asthma therapeutics market is expected to exhibit a CAGR of 2.9% during the forecast period (2020-2027) owing to collaborations among key players.

Intensive Care Unit (ICU) Equipment: Global Markets

Monday, July 27, 2020 - 2:00pm

The global market for ICU equipment generally consists of the following devices: ICU beds, mechanical ventilators; cardiac monitors; and continuous patient monitoring devices and feeding devices.

Key Points: 
  • The global market for ICU equipment generally consists of the following devices: ICU beds, mechanical ventilators; cardiac monitors; and continuous patient monitoring devices and feeding devices.
  • The scope of the report includes an overview of the global market for ICU equipment and analyses of global market trends, using 2019 as the base year and forecasting 2020 through 2025 with compound annual growth rate (CAGR) projections.
  • It also explains the major drivers and regional dynamics of the global market and current trends within the industry.
  • The report concludes with detailed profiles of the major vendors in the global market for ICU equipment.

Detailed Insights on the COVID-19 Safety and Prevention Products Market to 2025 - Ventilators to Record a Major Share of the Market Studied - ResearchAndMarkets.com

Monday, July 27, 2020 - 8:23am

The "COVID-19 Safety and Prevention Products Market - Growth, Trends, Forecast (2020-2025)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "COVID-19 Safety and Prevention Products Market - Growth, Trends, Forecast (2020-2025)" report has been added to ResearchAndMarkets.com's offering.
  • Additionally, strong public health measures and surveillance capacity have become an essential factor to prepare, prevent, and respond to health emergencies.
  • The company has build bag valve mask type ventilators to simplify design and to scale up capacity.
  • GM, also designed its V+Pro ventilator model as an upgrade to the one offered by Ventec for speeding up and optimizing production.

BREZTRI AEROSPHERE approved in the US for the maintenance treatment of COPD

Friday, July 24, 2020 - 1:10pm

BREZTRI AEROSPHERE has demonstrated significant benefits in reducing exacerbations in patients suffering from COPD.

Key Points: 
  • BREZTRI AEROSPHERE has demonstrated significant benefits in reducing exacerbations in patients suffering from COPD.
  • In both trials, the safety and tolerability of BREZTRI AEROSPHERE were consistent with the profiles of the dual comparators.
  • BREZTRI AEROSPHERE is not indicated for the relief of acute bronchospasm or for the treatment of asthma in the US or other countries.
  • BREZTRI AEROSPHERE is approved in Japan and China for patients with COPD and under regulatory review in the EU.

ERT Introduces Industry's First Fully Compliant Respiratory Solution in Adherence with New ATS/ERS Guidelines

Thursday, July 23, 2020 - 5:30pm

These enhancements make it the industry's first respiratory solution to achieve full compliance with standards issued by the American Thoracic Society and European Research Society (ATS / ERS) in 2019.

Key Points: 
  • These enhancements make it the industry's first respiratory solution to achieve full compliance with standards issued by the American Thoracic Society and European Research Society (ATS / ERS) in 2019.
  • "We're pleased to add the industry's first complete ATS/ERS 2019-compliant respiratory solution to the long list of innovations ERT has introduced to help our customers bring new treatments to patients sooner," said Achim Schlke, Executive Vice President, Respiratory Solutions at ERT.
  • Pharma companies, biotechs, and CROs have relied on ERT solutions across 15,000 studies, spanning more than four million patients to date.
  • By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly and with confidence.